On October 23, 2026, Balchem Corporation reported its financial results for the third quarter of 2026, which ended on September 30, 2026. The company reported net sales of $290.7 million for the quarter, representing an increase of 8.6% compared to the same period in the prior year. Net earnings for the quarter were $46.7 million, a rise of 16.0% year-over-year. The company also reported adjusted EBITDA of $80.3 million, an increase of 12.4% from the prior year.
On a per-share basis, GAAP earnings per share were $1.46, compared to $1.24 in the prior year quarter. Adjusted earnings per share were $1.57, up from $1.35 in the prior year. The company reported cash flows from operations of $69.8 million and free cash flow of $57.9 million.
Segment performance was strong across all three of Balchem’s reporting segments. The Human Nutrition and Health segment generated record quarterly sales of $188.2 million, an increase of 8.1% compared to the prior year quarter. The Animal Nutrition and Health segment saw quarterly sales of $63.0 million, an increase of 11.7% compared to the prior year quarter. The Specialty Products segment generated quarterly sales of $37.3 million, an increase of 4.5% compared to the prior year quarter.
Balchem repurchased approximately $28 million of common stock during the third quarter. Over the trailing twelve months, the company repurchased approximately $127 million of common stock. As of September 30, 2026, the company’s cash balance was $66.3 million and its net debt was $57.7 million, with an overall leverage ratio of 0.2 times on a net debt basis.
